Pepgen reports new data from IND-enabling studies of PGN-EDODM1 for DM1

Dec. 9, 2022

Pepgen Inc. has announced new preclinical data supporting the progression into clinical trials of PGN-EDODM1, its product candidate in development for the treatment of myotonic dystrophy type 1 (DM1).

BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2026.

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...